ACTIVE HALF-LIFE
2 days
CLASSIFICATION
Non-steroidal aromatase inhibitor
DOSAGE
0.5 - 2.5 mg/day
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Beligas - US
LAB TEST
See Document
WAREHOUSE
USA Warehouse 2
SUBSTANCE
Letrozole
Introducing Mono-Femara, a powerful non-steroidal aromatase inhibitor designed to effectively inhibit estrogen synthesis and combat cancer growth. As a cutting-edge third-generation aromatase inhibitor, Mono-Femara selectively and reversibly blocks aromatase, offering a promising solution for individuals facing estrogen-dependent breast cancer challenges.
Aromatase, a cytochrome P-450 enzyme found in various tissues, including the ovaries, liver, and breasts, plays a crucial role in converting androgens like androstenedione and testosterone into estrogens such as estrone and estradiol. Mono-Femara works by competitively and reversibly binding to the heme component of this enzyme, thereby halting estrogen production without impacting the synthesis of mineralocorticoids or corticosteroids. Unlike tamoxifen, which acts as an anti-estrogen by blocking estrogen receptors, Mono-Femara targets the source of estrogen itself.
Approved by the United States Food and Drug Administration (FDA) for treating hormone receptor-positive or unknown receptor status local or metastatic breast cancer in postmenopausal women, Mono-Femara can significantly lower estrogen levels by up to 98%, while simultaneously increasing testosterone levels. However, it?s important to note that side effects may mirror those associated with low estrogen levels, and long-term use could raise concerns about osteoporosis. To mitigate this risk, healthcare providers often recommend co-administering medications like Fosamax.
Athletes and bodybuilders particularly favor Mono-Femara for its ability to prevent water retention and the development of gynecomastia that can arise during steroid cycles. However, it?s essential to be mindful of dosage; exceeding 2.5 mg/day may temporarily reduce libido, and prolonged use above 5 mg/day might lead to kidney complications.
Moreover, Mono-Femara has shown potential in delaying the fusion of growth plates in adolescents, potentially enhancing the efficacy of growth hormone, making it a viable option for treating short stature in younger populations.